3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
7
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
21
Brain Neoplasms
9
Medulloblastoma
7
Central Nervous System Neoplasms
7
Lymphoma
6
Glioma
6
Astrocytoma
5
Oligodendroglioma
4
Recurrence
3
Gliosarcoma
3
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Ependymoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, AIDS-Related
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Familial ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Surveys and Questionnaires
114
Exercise
103
Blood Specimen Collection
99
Radiotherapy
66
Gemcitabine
64
Bevacizumab
57
Standard of Care
56
Cisplatin
55
Cyclophosphamide
51
Capecitabine
50
Carboplatin
49
Docetaxel
47
pembrolizumab
46
Dexamethasone
46
Paclitaxel
45
Interviews as Topic
43
Oxaliplatin
40
Magnetic Resonance Spectroscopy
39
Fluorouracil
37
Methods
36
Irinotecan
36
Therapeutics
33
Drug Therapy
32
Radiosurgery
31
Nivolumab
30
Erlotinib Hydrochloride
27
Educational Status
26
Everolimus
24
Leucovorin
23
Control Groups
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms
×
Lomustine
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled